Innovation all for the patients

CHUGAI

Roche A member of the Roche group

CHMP Recommends EU Approval of Alecensa as an Adjuvant Treatment for Resected ALK-Positive Early-Stage Lung Cancer

TOKYO, April 30, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued an Investor Update regarding anti-cancer agent/ALK inhibitor Alecensa® (alectinib). The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve Alecensa monotherapy as adjuvant treatment following complete tumor resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer at high risk of recurrence*.

*Stage IB (tumours ≥ 4 cm) - IIIA non-small cell lung cancer (UICC/AJCC 7th edition)

Please refer to the link below for details of the Investor Update:

CHMP recommends EU approval of Roche's Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
https://www.roche.com/investors/updates/inv-update-2024-04-26

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp